In the phase 1b-2 PANACEA Keynote-014 trial, pembrolizumab in combination with trastuzumab was evaluated in trastuzumab-resistant, advanced, and HER2+ breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.